ReviewBMB reports2015
Therapeutic aptamers: developmental potential as anticancer drugs.
Review in BMB reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Aptamers as an approach to targeted cancer therapy.Cancer cell international · 2024Review
- Aptamer-Based Tumor-Targeted Diagnosis and Drug Delivery.Advances in experimental medicine and biology · 2023Review
- Therapeutic Potential of Aptamer-Protein Interactions.ACS pharmacology & translational science · 2022Review
- Recent Advances in Aptasensor for Cytokine Detection: A Review.Sensors (Basel, Switzerland) · 2021Review
- Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach.International journal of molecular sciences · 2021Review
- Dimeric and Multimeric DNA Aptamers for Highly Effective Protein Recognition.Molecules (Basel, Switzerland) · 2020Review
- Novel insights into the role of aptamers in the fight against cancer.Journal of cancer research and clinical oncology · 2019Review
- Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood.Cancers · 2019Article
- Inhibition of Colorectal Cancer Cell Proliferation by Regulating Platelet-Derived Growth Factor B Signaling with a DNA AptamerAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Designed and Evolved Nucleic Acid Nanotechnology: Contrast and Complementarity.Bioconjugate chemistry · 2019Review
- Radiolabelled Aptamers for Theranostic Treatment of Cancer.Pharmaceuticals (Basel, Switzerland) · 2018Review
- The anti-tumor diterpene oridonin is a direct inhibitor of Nucleolin in cancer cells.Scientific reports · 2018Article
- RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity In Vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Aptamers in the Therapeutics and Diagnostics Pipelines.Theranostics · 2018Review
- Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low levels of Nucleolin.Scientific reports · 2017Article
- Review
- Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth.Molecular therapy. Nucleic acids · 2017Article
- Aptamers as the Agent in Decontamination Assays (Apta-Decontamination Assays): From the Environment to the Potential ApplicationJournal of nucleic acids · 2017Review
- Recent Methods for Purification and Structure Determination of Oligonucleotides.International journal of molecular sciences · 2016Review
- Therapeutic nucleic acids: current clinical status.British journal of clinical pharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aptamers, composed of single-stranded DNA or RNA oligonucleotides that interact with target molecules through a specific three-dimensional structure, are selected from pools of combinatorial oligonucleotide libraries. With their high specificity and affinity for target proteins, ease of synthesis and modification, and low immunogenicity and toxicity, aptamers are considered to be attractive molecules for development as anticancer therapeutics. Two aptamers - one targeting nucleolin and a second targeting CXCL12 - are currently undergoing clinical trials for treating cancer patients, and many more are under study. In this mini-review, we present the current clinical status of aptamers and aptamer-based cancer therapeutics. We also discuss advantages, limitations, and prospects for aptamers as cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.